COMPARATIVE ANALYSIS OF IN-STENT RESTENOSIS IN DIABETIC AND NON-DIABETIC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN PAKISTAN

T SHAH; HR VISHNO; SM SHAH; R ULLAH

doi:10.54112/bcsrj.v2024i1.983

Authors

T SHAH Hayatabad Medical complex Peshawar, Pakistan
HR VISHNO National Institute of Cardiovascular Diseases, Karachi, Pakistan
SM SHAH Kuwait teaching hospital, Peshawar, Pakistan
R ULLAH Kuwait teaching hospital, Peshawar, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.983

Keywords:

Coronary artery disease, , percutaneous coronary intervention, , in-stent restenosis,, diabetes, , drug-eluting stents, , risk factors, , Pakistan,

Abstract

Coronary artery disease (CAD) is a major global killer. Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) has improved CAD treatment. However, in-stent restenosis (ISR) remains a significant issue, especially for diabetic patients. Objective: This study aimed to compare ISR rates between diabetic and non-diabetic patients after PCI in a Pakistani hospital. Methods: We conducted a cross-sectional survey at Hayatabad Medical Complex, Peshawar, from January to December 2023. The study involved 273 patients aged 40-85 who underwent PCI with DES. Participants were split into diabetic and non-diabetic groups. Those with chronic kidney disease, previous coronary artery bypass graft surgery, or incomplete follow-up data were excluded. Data were gathered from medical records. ISR was marked by a luminal diameter reduction of more than 50% within the stent or 5 mm of its edges. We used chi-square tests and logistic regression for analysis, employing SPSS version 26.0. Results: The ISR rate was 23% overall. Diabetic patients showed a higher ISR rate (30%) than non-diabetic patients (16%). Logistic regression revealed diabetes (OR = 2.1, 95% CI: 1.3-3.2, p < 0.01), hypertension (OR = 1.8, 95% CI: 1.1-2.9, p < 0.05), and smoking (OR = 1.6, 95% CI: 1.0-2.5, p < 0.05) as significant predictors of ISR. Conclusion: This study highlights a higher ISR incidence in diabetic patients post-PCI. It underscores the need for meticulous monitoring and tailored strategies for this high-risk group. Managing hypertension, smoking, and dyslipidemia is essential to lower ISR rates and enhance outcomes.

Downloads

Download data is not yet available.

References

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528.

Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109(16):1942-7.

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-51.

Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Jama. 2002;287(19):2570-81.

Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial. European heart journal. 2004;25(2):107-12.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873-91.

Weintraub WS, Grau-Sepulveda MV, Weiss JM, DeLong ER, Peterson ED, O'Brien SM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation. 2012;125(12):1501-10.

Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100(2):153-9.

Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolín R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112(14):2175-83.

Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circulation: Cardiovascular Interventions. 2010;3(6):602-10.

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New England Journal of Medicine. 2003;349(14):1315-23.

Palmerini T, Dangas G, Mehran R, Caixeta A, Généreux P, Fahy MP, et al. Predictors and implications of stent thrombosis in non–ST-segment elevation acute coronary syndromes: the ACUITY trial. Circulation: Cardiovascular Interventions. 2011;4(6):577-84.

Fajadet J, Chieffo A. Current management of left main coronary artery disease. European heart journal. 2012;33(1):36-50.

Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Kardiologia Polska (Polish Heart Journal). 2014;72(12):1253-379.

Members ATF, Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). European heart journal. 2012;33(20):2569-619.